Evidence map›Paper›PMID 27830089›Full record

ArticleInternational journal of nephrology2016

Proteasome Activators, PA28

Saeed Yadranji Aghdam, Ali Mahmoudpour

Open access · goldAbstract read
In one paragraph

Article in International journal of nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Saeed Yadranji AghdamReynolds Institute on Aging, Room No. 4151, 629 Jack Stephens Drive, Little Rock, AR 72205, USA; Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.ORCID 0000-0001-7865-4854
Ali MahmoudpourNorgen Biotek Corp., 3430 Schmon Parkway, Thorold, ON, Canada L2V 4Y6.
Institute on Aging · USNorgen Biotek Corporation (Canada) · CA

Funding

UW Vision Research Core - Administrative CoreP30EY016665 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI Donna M Peters · 2005 to 2026
$12.6M
Integrated Multidisciplinary Strategies for Detection of Diabetic RetinopathiesRC4EY021357 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI ASSADI, AMIR H, ASSADI-PORTER, FARIBA M · 2010 to 2010
$3.2M
NEI NIH HHS P30 EY016665NEI NIH HHS RC4 EY021357
6 · The paper itself

Abstract

Diabetic nephropathy (DN) and diabetic retinopathy (DR) are major complications of type 1 and type 2 diabetes. DN and DR are mainly caused by injury to the perivascular supporting cells, the mesangial cells within the glomerulus, and the pericytes in the retina. The genes and molecular mechanisms predisposing retinal and glomerular pericytes to diabetic injury are poorly characterized. In this study, the genetic deletion of proteasome activator genes, PA28

Identifiers

PMID27830089
PMCPMC5088333
OpenAlexW2534466749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.